Cargando…

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response

Background: LC has been associated with hyporesponsiveness to several vaccines. Nonetheless, no data on complete serological and B- and T-cell immune response are currently available. Aims: To assess, in comparison with healthy controls of the same age and gender, both humoral and cellular immunores...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giambra, Vincenzo, Piazzolla, Annarita Valeria, Cocomazzi, Giovanna, Squillante, Maria Maddalena, De Santis, Elisabetta, Totti, Beatrice, Cavorsi, Chiara, Giuliani, Francesco, Serra, Nicola, Mangia, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9415026/ https://www.ncbi.nlm.nih.gov/pubmed/36016169 http://dx.doi.org/10.3390/vaccines10081281

Ejemplares similares

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)
por: Mangia, Alessandra, et al.
Publicado: (2022)

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose
por: Mangia, Alessandra, et al.
Publicado: (2022)

HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy
por: Mangia, Alessandra, et al.
Publicado: (2023)

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

Associations between Allelic Variants of the Human IgH 3′ Regulatory Region 1 and the Immune Response to BNT162b2 mRNA Vaccine
por: Colucci, Mattia, et al.
Publicado: (2021)

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study
por: Mangia, Alessandra, et al.
Publicado: (2022)

Serum C reactive protein predicts humoral response after BNT162b2 booster administration
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Humoral and cellular response after BNT162b2 vaccine booster in hemodialysis patients and kidney transplant recipients
por: De Cagna, Maria Rosaria, et al.
Publicado: (2023)

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination
por: Bauernfeind, Stilla, et al.
Publicado: (2022)

Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
por: Mangia, Alessandra, et al.
Publicado: (2020)

BNT162b2 Vaccine Booster and Mortality Due to Covid-19
por: Arbel, Ronen, et al.
Publicado: (2021)

Frosted branch angiitis after booster vaccination with BNT162b2
por: Haas, A.-M., et al.
Publicado: (2023)

Decline of immune humoral response after BNT162b2 vaccine
por: Ferri, Sonia, et al.
Publicado: (2022)

Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy
por: Terpos, Evangelos, et al.
Publicado: (2022)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
por: Gianserra, Laura, et al.
Publicado: (2022)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
por: Zurac, Sabina, et al.
Publicado: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
por: Çulpan, Hazal Cansu, et al.
Publicado: (2023)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
por: Miyazaki, Ryoichi, et al.
Publicado: (2023)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
por: Hertz, Tomer, et al.
Publicado: (2023)

Protection against Covid-19 by BNT162b2 Booster across Age Groups
por: Bar-On, Yinon M., et al.
Publicado: (2021)

Adverse reactions of BNT162b2 vaccine booster against COVID‐19 in Japan
por: Nishizawa, Toshinori, et al.
Publicado: (2022)

Humoral Serologic Response to the BNT162b2 Vaccine Afterallogeneic Haematopoietic Cell Transplantation
por: Yeshurun, Moshe, et al.
Publicado: (2021)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study
por: GIUBELAN, LUCIAN-ION, et al.
Publicado: (2022)

Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases
por: Leung, Daniel, et al.
Publicado: (2023)

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
por: Li, Rui, et al.
Publicado: (2022)

Acute myopericarditis following administration of the BNT162b2 booster vaccine against COVID19
por: Sivan, S.K., et al.
Publicado: (2022)

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine
por: Azzi, Lorenzo, et al.
Publicado: (2023)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant Recipients
por: Hod, Tammy, et al.
Publicado: (2022)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults
por: Dedroogh, Simon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5a9d9n76k61mltqv9ipmv04qhv